For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Share-based compensation | - | 389,114 | ||
| Other segment items | - | 396,481 | ||
| Professional fees | - | 543,168 | ||
| Operating expenses-CTIM76 | - | 1,445,862 | ||
| Operating expenses-CT95 | - | 1,488,530 | ||
| Operating expenses-CT202 | - | 3,149,238 | ||
| Research and development | 8,722,104 | - | ||
| Personnel-related costs | - | 2,345,969 | ||
| General and administrative | 1,888,376 | - | ||
| Loss from operations | -10,610,480 | -9,758,362 | ||
| Other income (expense) | - | 27,080 | ||
| Interest income | - | 903,772 | ||
| Net loss | - | -8,827,510 | ||
| Net income (loss) per share - basic (in dollars per share) | -0.1 | - | ||
| Net income (loss) per share - diluted (in dollars per share) | -0.1 | - | ||
| Weighted average common shares outstanding - basic (in shares) | 95,185,187 | - | ||
| Weighted average common shares outstanding - diluted (in shares) | 95,185,187 | - | ||
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)